Association between prurigo nodularis and substance use disorders

Taylor, Mercedes K.; Bordeaux, Zachary A.; Deng, Junwen; Parthasarathy, V.; Adawi, Waleed; Oladipo, Olusola O.; Alajmi, Ali; Lee, Kevin K.; Marani, Melika; Cornman, Hannah; Kambala, Anusha; Gabriel, Sylvie; Kwatra, Shawn G.

doi:10.1111/bjd.21676

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though the precise etiology and pathogenesis of CPG remain obscure, due to the presence of lymphocytes, mast cells, and eosinophils in the prurigo skin and the effectiveness of certain antiinflammatory medications, it is believed that CPG is principally a generalized inflammatory disease [1][2][3][4][5][6][7]. In addition, some reports have shown that prurigo lesions were also improved with effective treatment of certain comorbidities that can lead to itching [8][9][10][11]. All these findings suggest that there are intersections between CPG and other comorbidities.…”

Section: Introductionmentioning

confidence: 99%

Comorbidities of Chronic Prurigo: A Systematic Review and Meta-Analysis

Yin,

Yang,

Guo

et al. 2023

Dermatology

View full text Add to dashboard Cite

Background: Chronic prurigo (CPG) is an inflammatory skin disease. Comorbidities including dermatological, cardiovascular, and psychiatric diseases have been reported in patients with CPG, however, the evidence has not been systematically evaluated. We aim to summarize the comorbidities, discuss underlying pathogenesis, and highlight the evaluation of CPG patients. Methods: We performed a systematic search using PubMed, Embase, and Web of Science databases for all articles reporting possible associated diseases with CPG. Pooled random-effects odds ratios (OR) with 95% CI were calculated. Results: A total of 17 studies were included in this systematic review. Statistically significant association(P<0.05) with CPG has been demonstrated with atopic diseases: atopic dermatitis (pooled OR, 10.91; 95% CI, 3.65-32.67), allergic rhinitis (2.66;1.12-6.27), asthma (3.23;1.55-6.74); infectious diseases: hepatitis B (pooled OR, 2.15; 95% CI, 1.11-4.14); endocrine diseases: diabetes (pooled OR, 4.93; 95% CI, 1.13-21.56), type 1 diabetes 2.46;2.16-2.81), type 2 diabetes (1.89;1.34-2.68), hyperlipoproteinemia (2.90; 1.61-5.22); cardiovascular diseases: heart failure (pooled OR, 4.13; 95% CI, 1.15-14.91), hypertension (3.17;1.56-6.45); respiratory system diseases: chronic obstructive pulmonary disease (pooled OR, 3.19; 95% CI, 1.42-7.16); urinary system diseases: chronic kidney disease (pooled OR, 4.16; 95% CI, 1.79-9.66); digestive system disease: inflammatory bowel disease (pooled OR, 2.06; 95% CI, 1.26-3.36); and others: osteoporosis (pooled OR, 3.08; 95% CI, 1.70-5.59), thyroid disease (1.70;1.17-2.47). Conclusion: CPG is associated with various systemic disorders. Recognition of comorbidities is critical to the appropriate management of affected patients.

show abstract